Da en tidligere behandlet patient behandlet med BeneFIX under kliniske afprøvninger udviklede en klinisk relevant svagt reagerende inhibitor, og da erfaring fra antigener med rekombinant faktor IX er stadig begrænset, skal De under behandling med BeneFIX omhyggeligt overvåges for udviklingen af faktor IX inhibitorer.
Since during clinical studies one PTP treated with BeneFIX developed a clinically relevant low responding inhibitor, and experience on antigenicity with recombinant factor IX is still limited, while being treated with BeneFIX you should be carefully monitored for the development of factor IX inhibitors.